Abstract: The invention relates to the use of an anti-tumour vaccine composed of two peptides of nine amino acids—native cryptic TERT572 (RLFFYRKSV, SEQ ID No. 1), expressed by tumour cells, and the optimised variant thereof TERT572Y (YLFFYRKSV, SEQ ID No. 2), for the treatment of a tumour expressing telomerase reverse transcriptase (TERT), in an HLA-A*0201 patient with a normal gamma glutamine transferase (gGT) level and/or a normal lactate dehydrogenase (LDH) level.

Abstract: The invention pertains to the use of a tumor vaccine composed of two peptides of nine amino acids—the WT cryptic TERT572 (RLFFYRKSV, SEQ ID No: 1) expressed by tumor cells and its optimized variant TERT572Y (YLFFYRKSV, SEQ ID No: 2)—for treating cancer in a HLA-A*0201-positive patient having a non-immunogenic tumor expressing TERT.

Abstract: The invention pertains to the use of a tumor vaccine composed of two peptides of nine amino acids—the WT cryptic TERT572 (RLFFYRKSV, SEQ ID No: 1) expressed by tumor cells and its optimized variant TERT572Y (YLFFYRKSV, SEQ ID No: 2)—for treating cancer in a HLA-A*0201-positive patient having a non small cell lung cancer (NSCLC) expressing TElomerase Reverse Transcriptase (TERT), wherein said patient is a never-smoker or a light-former smoker.

Abstract: The present invention relates to a method for preparing a vaccine formulation with an optimized polypeptide comprising three epitopes and MONTANIDE as adjuvant, for use in anti-cancer immunotherapy for administration to a human subject.

Abstract: The present invention provides novel methods and materials for efficiently treating patients having an HLA-B*0702 phenotype, based on peptides representing shared epitopes of tumor antigens. In particular, the invention relates to a method for identifying a HLA-B*0702-restricted peptide which can trigger a cytotoxic response against several antigens from one single multigenic family, and to several such epitopes.

Abstract: The invention provides methods for identifying a HLA-B*0702-restricted cryptic epitope in an antigen, as well as methods for increasing the immunogenicity of HLA-B*0702-restricted cryptic epitopes. The HLA-B*0702-restricted cryptic epitopes and their cognate immunogenic epitopes are useful for stimulating an immune reaction against the cryptic epitopes in a subject. Accordingly, the invention further provides pharmaceutical compositions comprising a HLA-B*0702-restricted cryptic epitope or a cognate immunogenic epitope thereof, and vaccination kits comprising such epitopes. The novel materials of the invention are particularly useful for efficiently treating patients having an HLA-B*0702 phenotype.

Abstract: The invention pertains to an optimized chimeric polypeptide for use in HLA-337 cancer patients, which comprises four optimized peptides derived from cryptic tumor epitopes (CEA, TERT, MAGE and HER-2/neu) to enhance their immunogenicity.

Abstract: The present invention relates to a method for preparing a vaccine formulation with an optimized polypeptide comprising three epitopes and MONTANIDE as adjuvant, for use in anti-cancer immunotherapy for administration to a human subject.

Abstract: The present invention discloses peptides such as an isolated peptide consisting of an immunogenic HLA-A*2402-restricted epitope. For example, the isolated peptide may be selected from the group consisting of KYGVLLKTL (SEQ ID NO:11); RYMRQFVAL (SEQ ID NO: 12); RYVSRLLGI (SEQ ID NO: 13); RYGKGWDLL (SEQ ID NO: 14); RYLVQVQAL (SEQ ID NO: 15); and RYWELSNHL (SEQ ID NO: 16).

Abstract: The invention provides methods for identifying a HLA-B*0702-restricted cryptic epitope in an antigen, as well as methods for increasing the immunogenicity of HLA-B*0702-restricted cryptic epitopes. The HLA-B*0702-restricted cryptic epitopes and their cognate immunogenic epitopes are useful for stimulating an immune reaction against the cryptic epitopes in a subject. Accordingly, the invention further provides pharmaceutical compositions comprising a HLA-B*0702-restricted cryptic epitope or a cognate immunogenic epitope thereof, and vaccination kits comprising such epitopes. The novel materials of the invention are particularly useful for efficiently treating patients having an HLA-B*0702 phenotype.

Abstract: The invention provides methods for identifying a HLA-B*0702-restricted cryptic epitope in an antigen, as well as methods for increasing the immunogenicity of HLA-B*0702-restricted cryptic epitopes. The HLA-B*0702-restricted cryptic epitopes and their cognate immunogenic epitopes are useful for stimulating an immune reaction against the cryptic epitopes in a subject. Accordingly, the invention further provides pharmaceutical compositions comprising a HLA-B*0702-restricted cryptic epitope or a cognate immunogenic epitope thereof, and vaccination kits comprising such epitopes. The novel materials of the invention are particularly useful for efficiently treating patients having an HLA-B*0702 phenotype.

Abstract: The present invention provides novel methods and materials for efficiently treating patients having an HLA-B*0702 phenotype, based on peptides representing shared epitopes of tumour antigens. In particular, the invention relates to a method for identifying a HLA-B*0702-restricted peptide which can trigger a cytotoxic response against several antigens from one single multigenic family, and to several such epitopes.

Abstract: The present invention pertains to methods for identifying a HLA-A*2402-restricted cryptic epitope in an antigen, and for increasing its immunogenicity, in order to obtain HLA-A*2402-restricted epitopes able to trigger an immune response against HLA-A*2402-restricted cryptic epitopes. Isolated peptides consisting of cryptic or optimized HLA-A*2402-restricted epitopes are provided.

Abstract: The present invention relates to the field of peptide immunotherapy. In particular, the invention pertains to a method for identifying a HLA-B*0702-restricted cryptic epitope in an antigen, and to a method for increasing its immunogenicity. The invention also provides novel methods and materials for efficiently treating patients having an HLA-B*0702 phenotype.

Abstract: This invention relates to the field of anticancer therapy, and to the identification of immunogenic peptides derived from the human telomerase reverse transcriptase (hTERT). The present invention relates to polynucleotides encoding hTERT epitopes restricted to MHC class I molecule, analogues thereof and polyepitopes containing such epitopes and/or analogues. Are also included in the present invention, vector and cell comprising such polynucleotides. The present invention also concerns composition comprising hTERT polypeptides, corresponding polynucleotides, vectors and cells, for use in the treatment and/or prevention of cancer.

Abstract: This invention relates to the field of anticancer therapy, and to the identification of immunogenic peptides derived from the human telomerase reverse transcriptase (hTERT). The present invention relates to polynucleotides encoding hTERT epitopes restricted to MHC class I molecule, analogues thereof and polyepitopes containing such epitopes and/or analogues. Are also included in the present invention, vector and cell comprising such polynucleotides. The present invention also concerns composition comprising hTERT polypeptides, corresponding polynucleotides, vectors and cells, for use in the treatment and/or prevention of cancer.